Moon­Lake's PhII da­ta on skin dis­ease set it up against Cosen­tyx, UCB and oth­ers in IL-17 field

Moon­Lake Im­munother­a­peu­tics says it’s cleared the bar in a Phase II tri­al of its IL-17A and IL-17F in­hibitor in hidradeni­tis sup­pu­ra­ti­va.

In its 234-pa­tient …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER